Skandinaviska Enskilda Banken Ab (Publ) Denali Therapeutics Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

$21.6 Billion
Q4 2024

A detailed history of Skandinaviska Enskilda Banken Ab (Publ) transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Skandinaviska Enskilda Banken Ab (Publ) holds 43,245 shares of DNLI stock, worth $896,468. This represents 0.0% of its overall portfolio holdings.

Number of Shares

43,245

Previous 43,245 -0.0%

Holding current value

$896,468

Previous $1.26 Million 30.02%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$15.83 - $23.35 $4.83 Million - $7.12 Million	-304,958 Reduced 87.58%	43,245 $887,000
Q2 2023 Aug 07, 2023	BUY	$23.37 - $32.96 $963,615 - $1.36 Million	41,233 Added 13.43%	348,203 $10.3 Million
Q1 2023 May 11, 2023	SELL	$21.91 - $32.67 $46,493 - $69,325	-2,122 Reduced 0.69%	306,970 $7.07 Million
Q4 2022 Feb 08, 2023	BUY	$26.28 - $33.92 $467,363 - $603,233	17,784 Added 6.1%	309,092 $8.6 Million
Q3 2022 Nov 14, 2022	BUY	$25.97 - $38.53 $2.04 Million - $3.02 Million	78,485 Added 36.88%	291,308 $8.94 Million
Q2 2022 Aug 10, 2022	BUY	$20.88 - $35.19 $1.55 Million - $2.62 Million	74,324 Added 53.66%	212,823 $6.26 Million
Q1 2022 May 11, 2022	SELL	$29.0 - $47.27 $1,856 - $3,025	-64 Reduced 0.05%	138,499 $4.46 Million
Q4 2021 Feb 10, 2022	BUY	$42.59 - $55.02 $277,218 - $358,125	6,509 Added 4.93%	138,563 $6.24 Million
Q3 2021 Nov 10, 2021	BUY	$48.48 - $78.23 $4.96 Million - $8 Million	102,269 Added 343.36%	132,054 $6.66 Million
Q2 2021 Aug 10, 2021	BUY	$50.3 - $78.44 $185,355 - $289,051	3,685 Added 14.12%	29,785 $2.34 Million
Q4 2020 Feb 11, 2021	BUY	$36.89 - $93.56 $962,829 - $2.44 Million	26,100 New	26,100 $2.19 Million

Others Institutions Holding DNLI

# of Institutions

241

Shares Held

121M

Call Options Held

80K

Put Options Held

36.8K

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.78B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.

Account

Skandinaviska Enskilda Banken Ab (Publ) Denali Therapeutics Inc. Transaction History